Stoke Therapeutics Inc

Stoke Therapeutics has completed enrollment of 162 patients in its Phase III EMPEROR study of zorevunersen for Dravet syndrome, positioning the company for a data readout in the third quarter of 2027. The study has seen zero patient discontinuations to date, compared to the 15% rate assumed in the original statistical powering, and 60 patients have already reached the week 28 primary endpoint milestone. Management plans to initiate a rolling New Drug Application submission in the first quarter of 2027, supported by a pro forma cash position of approximately $420 million, which is expected to fund operations through a potential U.S. launch in early 2028. The company also reported progress in its pipeline, including dose escalation in the Phase I study of STK-002 for autosomal dominant optic atrophy and lead optimization for SYNGAP1-related disorders.